Ben Fidler
Senior Editor | @BentheFidlerBen is a senior editor for BioPharma Dive. He is a veteran business journalist with 15 years of experience covering a variety of sectors. Prior to joining Industry Dive, Ben spent six-plus years with Xconomy writing about biotech, specializing in unique angles, profiles, features, enterprise pieces and more. A lifelong New Yorker, Brooklyn transplant and Yankees/Giants/Knicks fan, Ben is trying to cope with a recent move to the suburbs of Virginia, where he spends most of his time chasing after his rambunctious toddler. Ben has a B.A. from Binghamton University.
838 articles by Ben Fidler
-
AbbVie pledges $100B to US production in drug pricing deal with Trump
Jan. 13, 2026 -
Eikon, a high-profile startup led by Merck vets, seeks an IPO
Jan. 11, 2026 -
Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies
Jan. 9, 2026 -
Novo launches Wegovy pill; Argenx to swap CEOs
Jan. 5, 2026 -
Radiopharmaceutical specialist Aktis seeks an IPO
Dec. 22, 2025 -
Cytokinetics set to battle Bristol Myers as FDA approves heart drug
Dec. 21, 2025 -
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
Dec. 18, 2025 -
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease
Dec. 15, 2025 -
Sobi snaps up gout drug in $950M deal for startup Arthrosi
Dec. 14, 2025 -
Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar
Dec. 8, 2025 -
Richard Pazdur, FDA drug czar, to retire from agency
Dec. 2, 2025 -
Belite continues ascent as Stargardt drug hits mark in late-stage trial
Dec. 1, 2025 -
FDA limits Elevidys use; Nxera to lay off staff
Nov. 17, 2025 -
Merck stakes $9.2B on Cidara and its long-acting flu drug
Nov. 14, 2025 -
FDA unveils new regulatory roadmap for bespoke drug therapies
Nov. 12, 2025 -
Metagenomi, Ovid CEOs step aside; Cogent soars on ‘unprecedented’ stomach cancer data
Nov. 12, 2025 -
Pfizer wins bidding war for Metsera with $10B offer
Nov. 8, 2025 -
Braveheart secures $185M to advance challenger to Bristol Myers heart drug
Nov. 5, 2025 -
Sarepta Duchenne drugs come up short in confirmatory test
Nov. 4, 2025 -
Pfizer sues Metsera, Novo in effort to enforce buyout deal
Nov. 1, 2025 -
Earnings roundup: Alnylam’s down day, Neurocrine’s head scratch and Biogen’s ‘low quality’ win
Oct. 30, 2025 -
BridgeBio chalks up another win for its rare disease research
Oct. 29, 2025 -
BioMarin, following sluggish sales, to offload hemophilia gene therapy
Oct. 27, 2025 -
BridgeBio to seek approval of limb-girdle drug following new study data
Oct. 27, 2025 -
Hemab collects another $157M to go after ‘underserved’ blood diseases
Oct. 27, 2025